Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + allopurinol
- Development stage
- Phase 4
- Lead developer
- Merck Research Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of two medications used concurrently: atorvastatin, a statin medication that lowers cholesterol by inhibiting HMG-CoA reductase, and allopurinol, a xanthine oxidase inhibitor that reduces uric acid production to treat gout and prevent kidney stones. This is not a fixed-dose combination product but rather two separate medications that may be prescribed together.
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on atorvastatin + allopurinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + allopurinol.